ABIOMED

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Whiting Petroleum

Owens-Illinois

Poor earnings and other concerns took these stocks down.

Why Whiting Petroleum, Owens-Illinois, and Abiomed Slumped Today

Abiomed, Inc. (ABMD) CEO Michael Minogue on Q1 2020 Results - Earnings Call Transcript

Shares sink after the company's earnings come up short and management cuts guidance.

Why Abiomed Stock Is Being Mauled Today

ABIOMED (ABMD) slashes revenue guidance for fiscal 2020.

ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan

Abiomed (ABMD) delivered earnings and revenue surprises of 1.01% and -1.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Q1 Earnings Beat Estimates

ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.

Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?

Align Technology

Advanced Micro Devices

Amazon

Global Payments

MarketAxess Holdings

MSCI

Netflix

NVIDIA

Take-Two Interactive Software

The S&P 500 jumped above 3,000 for the first time, nearly five years after the index hit 2,000. These are the stocks that powered the historic rally.

These are the stocks that have led the S&P 500's five-year run to 3,000 from 2,000

Cardinal Health

CannTrust Holdings

Find out why Cardinal Health, CannTrust Holdings, and Abiomed have our healthcare experts feeling giddy right now.

3 Top Healthcare Stocks to Buy

Amgen

Bristol-Myers

Stryker

Teladoc

These beaten-down healthcare stocks still have plenty of long-term potential. Here's what investors need to know about each.

5 Healthcare Stocks to Pick Up From the Wreckage

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

Why Is Abiomed (ABMD) Up 0.6% Since Last Earnings Report?

Abiomed (ABMD) closed the most recent trading day at $261.92, moving -1.68% from the previous trading session.

Abiomed (ABMD) Dips More Than Broader Markets: What You Should Know

Aptiv

Grupo Aeroportuario del Sureste SAB de CV

Intuit

Sarepta Therapeutics

Zoetis

Chief investment officer and chief executive officer of Sands Capital Management, Frank Sands (Trades, Portfolio), bought shares of the following stocks in the fourth quarter of 2018 and first quarter of 2019.

7 Stocks Frank Sands Continues to Buy

ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

Boston Scientific

Edwards Lifesciences

HCA Healthcare

Illumina

The health care sector should benefit from a shift towards more defensive names in 2019.

Top 5 Health Care Stocks of 2018 by Performance

ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.

ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals

The medical device maker failed to reach its financial targets in the final quarter of its fiscal year.

Abiomed Comes Up Short as Growth Slows

Abiomed, Inc. (ABMD) CEO Michael Minogue on Q1 2019 Results - Earnings Call Transcript

Abiomed earnings of $1.60 a share beat expectations, but $207.1 million in sales missed estimates. Sales guidance for fiscal 2020 also disappointed.

This Medtech Stock Plunged As Earnings Topped, But Sales Lagged

ABIOMED's (ABMD) Q4 results gain from solid Impella show in Japan.

ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan

Abiomed (ABMD) delivered earnings and revenue surprises of 0.00% and -4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Matches Q4 Earnings Estimates

ABIOMED's (ABMD) fourth-quarter results are likely to gain from flagship Impella despite foreign exchange headwinds.

Will Flagship Impella Drive ABIOMED's (ABMD) Q4 Earnings?

Intuitive Surgical

Teva Pharmaceutical

The healthcare sector is filled with opportunities for investors.

Top Healthcare Stocks to Buy Right Now

Disruptive Medical device company specializing in heart pumps for high risk heart surgery.

Abiomed: Upside That Will Get Your Heart Pumping

Abiomed (ABMD) closed the most recent trading day at $268.14, moving -1% from the previous trading session.

Abiomed Dips More Than Broader Markets

Thermo Fisher Scientific

TMO vs. ABMD: Which Stock Is the Better Value Option?

News for ABIOMED Stock (ABMD)